COPENHAGEN, Denmark , June 07, 2023 (GLOBE NEWSWIRE) -- Forward Pharma A/S (OTC:FWPAY) (“Forward” or the “Company”) today announced that its Board of Directors has approved a change in the number of its ordinary shares represented by American Depositary Shares (“ADSs”), issued by the Bank of New
COPENHAGEN, Denmark , Dec. 19, 2022 (GLOBE NEWSWIRE) -- Forward Pharma A/S (NASDAQ:FWP) (“we” or “Forward”), today announced that that on December 16, 2022 it received written notice from The Nasdaq Stock Market LLC (“Nasdaq”) notifying us that Nasdaq believes that Forward is a "public shell"
COPENHAGEN, Denmark , Dec. 06, 2022 (GLOBE NEWSWIRE) -- Forward Pharma A/S (NASDAQ:FWP) (“Forward” or the “Company”), today announced that the Enlarged Board of Appeal (the “EBA”) of the European Patent Office (the “EPO”) has denied Forward’s petition for review (the “Petition”) of the decision of
COPENHAGEN, Denmark , April 08, 2022 (GLOBE NEWSWIRE) -- Forward Pharma A/S (NASDAQ:FWP) (“we,” “Forward” or the “Company” and, together with its subsidiaries, the “Group”), today reported consolidated financial results for the year ended December 31, 2021 .
COPENHAGEN, Denmark , Sept. 06, 2021 (GLOBE NEWSWIRE) -- Forward Pharma A/S (NASDAQ:FWP) (“we,” “Forward” or the “Company”), today announced that the Technical Board of Appeal (the “TBA”) of the European Patent Office (the “EPO”) has dismissed Forward’s appeal of the previous decision of the EPO
COPENHAGEN, Denmark , April 14, 2021 (GLOBE NEWSWIRE) -- Forward Pharma A/S (NASDAQ:FWP) (“We,” “Forward” or the “Company” and, together with its subsidiaries, the “Group”), today reported consolidated financial results for the year ended December 31, 2020 .
COPENHAGEN, Denmark , Jan. 12, 2021 (GLOBE NEWSWIRE) -- Forward Pharma A/S (NASDAQ:FWP) (“we,” “Forward” or the “Company”), today announced that due to ongoing precautionary measures against the spread of the novel coronavirus (“COVID-19”), the Technical Board of Appeal (the “TBA”) of the European
COPENHAGEN, Denmark , May 12, 2020 (GLOBE NEWSWIRE) -- Forward Pharma A/S (NASDAQ:FWP) (“we,” “Forward” or the “Company”), today announced that due to current precautionary measures against the spread of the novel coronavirus (“COVID-19”), the Technical Board of Appeal (the “TBA”) of the European
COPENHAGEN, Denmark , April 24, 2020 (GLOBE NEWSWIRE) -- Forward Pharma A/S (NASDAQ:FWP) (“We,” “Forward” or the “Company” and, together with its subsidiaries, the “Group”), today reported consolidated financial and operating results for the year ended December 31, 2019 .
COPENHAGEN, Denmark , Nov. 26, 2019 (GLOBE NEWSWIRE) -- Forward Pharma A/S (NASDAQ:FWP) (“Forward” or the “Company”) today announced that its Board of Directors has approved a change in the number of its ordinary shares represented by American Depositary Shares (“ADSs”), issued by the Bank of New
COPENHAGEN, Denmark , Sept. 05, 2019 (GLOBE NEWSWIRE) -- Forward Pharma A/S (NASDAQ:FWP) (the “Company”) today announced that Chief Executive Officer, Dr. Claus Bo Svendsen, will participate in the Fall Investor Summit investor conference ( https://www.microcapconf.com ) in New York, NY . Dr.
COPENHAGEN, Denmark, June 26, 2019 (GLOBE NEWSWIRE) -- Forward Pharma A/S (NASDAQ: FWP ) (the “Company”) today announced its intention to transfer its public listing of American Depositary Shares from the Nasdaq Global Select Market to the Nasdaq Capital Market.
COPENHAGEN, Denmark , June 26, 2019 (GLOBE NEWSWIRE) -- Forward Pharma A/S (NASDAQ:FWP) (the “Company”) today announced its intention to transfer its public listing of American Depositary Shares from the Nasdaq Global Select Market to the Nasdaq Capital Market .
COPENHAGEN, Denmark , April 04, 2019 (GLOBE NEWSWIRE) -- Forward Pharma A/S (NASDAQ:FWP) (“We,” “Forward” or the “Company” and, together with its subsidiaries, the “Group”), today reported consolidated financial results for the year ended December 31, 2018 .
COPENHAGEN, Denmark , March 27, 2019 (GLOBE NEWSWIRE) -- Forward Pharma A/S (NASDAQ:FWP) (the “Company”) today announced that Dr. Claus Bo Svendsen, the Company’s Chief Executive Officer, will participate in the DKBIO2019 life science investor conference in New York, NY . Dr.
COPENHAGEN, Denmark , March 27, 2019 (GLOBE NEWSWIRE) -- Forward Pharma A/S (NASDAQ:FWP) (the “Company”) today announced that Dr. Claus Bo Svendsen, the Company’s Chief Executive Officer, will participate in the DKBIO2019 life science investor conference in New York, NY . Dr.
The U.S. Court of Appeals for the Federal Circuit has affirmed the decision of the Patent Trial and Appeal Board in the U.S. patent interference proceeding The appeal of the European EP2801355 patent opposition continues Forward expects to reduce operating expenses to match the current situation
COPENHAGEN, Denmark , Sept. 28, 2018 (GLOBE NEWSWIRE) -- Forward Pharma A/S (NASDAQ:FWP) (the “Company”) today announced that Dr. Claus Bo Svendsen, the Company’s Chief Executive Officer, will participate in the Ladenburg Thalmann 2018 Healthcare Conference in New York, NY . Dr.
COPENHAGEN, Denmark , Sept. 19, 2018 (GLOBE NEWSWIRE) -- Forward Pharma A/S (NASDAQ:FWP) (“We”, “Forward” or the “Company” and together with its subsidiaries, the “Group”), today reported consolidated financial results for the six-month period ended June 30, 2018 .
COPENHAGEN, Denmark , Aug. 23, 2018 (GLOBE NEWSWIRE) -- Forward Pharma A/S (NASDAQ:FWP) (the “Company”) today announced that Dr. Claus Bo Svendsen , the Company’s Chief Executive Officer, will participate in the LSX Nordic Congress being held August 29-30, 2018 in Stockholm, Sweden . Dr.
COPENHAGEN, Denmark , May 07, 2018 (GLOBE NEWSWIRE) -- Forward Pharma A/S (Nasdaq:FWP) (“We” or “Forward” or the “Company”), today announced the filing of a notice of appeal of the decision of the Opposition Division of the European Patent Office (the “EPO”) that revoked EP2801355 (the “’355
COPENHAGEN, Denmark , April 30, 2018 (GLOBE NEWSWIRE) -- Forward Pharma A/S (Nasdaq:FWP) (“We” or “Forward” or the “Company”), today reported financial results for the year ended December 31, 2017 . Net income for the year ended December 31, 2017 was $917.1 million , or $2.30 per diluted share,
COPENHAGEN, Denmark , Feb. 07, 2018 (GLOBE NEWSWIRE) -- Forward Pharma A/S (NASDAQ:FWP) (the “Company”) today announced that Dr. Claus Bo Svendsen , the Company’s Chief Executive Officer, will give a corporate update at the 7th Annual Leerink Partners Global Healthcare Conference in New York, NY .
Forward Pharma Expects to Appeal the Decision Upon Review COPENHAGEN, Denmark , Jan. 29, 2018 (GLOBE NEWSWIRE) -- Forward Pharma A/S (NASDAQ:FWP) (“Forward” or the “Company”) today announced that the European Patent Office (the “EPO”) has revoked the EP2801355 patent (the “’355 patent”) following
Oral argument expected in second or third quarter of 2018 COPENHAGEN, Denmark , Dec. 21, 2017 (GLOBE NEWSWIRE) -- Forward Pharma A/S (NASDAQ:FWP) (“Forward” or the “Company”) today announced the filing of its reply brief to the U.S. Court of Appeals for the Federal Circuit (the “Federal Circuit”)
COPENHAGEN, Denmark , Nov. 29, 2017 (GLOBE NEWSWIRE) -- Forward Pharma A/S (NASDAQ:FWP) (“Forward” or the “Company”) today announced the filing of further written submissions in the European Opposition Proceeding for the EP2801355 patent (“the ‘355 patent”) with the Opposition Division of the
COPENHAGEN, Denmark , Nov. 27, 2017 (GLOBE NEWSWIRE) -- Forward Pharma A/S (NASDAQ:FWP) (the “Company”) today announced that Dr. Claus Bo Svendsen , the Company’s Chief Executive Officer, will participate in two upcoming investor conferences in New York, NY . Dr.
COPENHAGEN, Denmark , Nov. 22, 2017 (GLOBE NEWSWIRE) -- Forward Pharma A/S (NASDAQ:FWP) (“Forward Pharma”) today announced the completion of its previously announced corporate restructuring plan (the “Restructuring”) substantially in the form set forth in Appendix D to the Settlement and License
COPENHAGEN, Denmark , Nov. 09, 2017 (GLOBE NEWSWIRE) -- Forward Pharma A/S (NASDAQ:FWP) (the “Company”) today announced that Dr. Claus Bo Svendsen , the Company’s Chief Executive Officer, will participate in the Nordic-American Life Science Conference being held November 13-14, 2017 in New York, NY
COPENHAGEN, Denmark , Sept. 26, 2017 (GLOBE NEWSWIRE) -- Forward Pharma A/S (NASDAQ:FWP) (“We” or “Forward” or the “Company”), today reported financial results for the six-month period ended June 30, 2017 . Net income for the six-month period ended June 30, 2017 was $941.2 million , or $1.91 per
COPENHAGEN, Denmark , Sept. 05, 2017 (GLOBE NEWSWIRE) -- Forward Pharma A/S (NASDAQ:FWP) (“Forward” or the “Company”) today announced the filing in the U.S. Court of Appeals for the Federal Circuit (the “Federal Circuit”) of the opening brief for the appeal of the PTAB decision that ended the
COPENHAGEN, Denmark , Sept. 01, 2017 (GLOBE NEWSWIRE) -- Forward Pharma A/S (NASDAQ:FWP) (“the Company” or “Forward”) today announced the final approval by the Company’s board of directors of the plans to return a total of EUR 917.7 million to its shareholders through a capital reduction (the
COPENHAGEN, Denmark , Aug. 02, 2017 (GLOBE NEWSWIRE) -- Forward Pharma A/S (NASDAQ:FWP) (“the Company” or “Forward”) today announced the result of the extraordinary general meeting of its shareholders held on August 2, 2017 (the “Extraordinary General Meeting”), where the requisite majority of the
COPENHAGEN, Denmark , July 18, 2017 (GLOBE NEWSWIRE) -- Forward Pharma A/S (NASDAQ:FWP) (“the Company” or “Forward”) today announced plans to return EUR 19.45 per share amounting to a total of EUR 917.7 million to its shareholders through a capital reduction.
COPENHAGEN, Denmark , June 14, 2017 (GLOBE NEWSWIRE) -- Forward Pharma A/S (NASDAQ:FWP) (the “Company”) today announced that Dr. Claus Bo Svendsen , the Company’s Chief Executive Officer, will present at the JMP Securities 2017 Life Sciences Conference being held June 20-21, 2017 in New York, NY .
COPENHAGEN, Denmark , June 02, 2017 (GLOBE NEWSWIRE) -- Forward Pharma A/S (NASDAQ:FWP) (the “Company”) today announced that Dr. Claus Bo Svendsen , the Company’s Chief Executive Officer, will present at the Jefferies 2017 Global Healthcare Conference being held June 6-9, 2017 in New York, NY . Dr.
COPENHAGEN, Denmark , May 31, 2017 (GLOBE NEWSWIRE) -- Forward Pharma A/S (NASDAQ:FWP) (“Forward” or the “Company”) today announced the filing of the notice of appeal of the PTAB decision that ended the interference proceeding between the Forward 11/576,871 patent application (the “’871
COPENHAGEN, Denmark , May 01, 2017 (GLOBE NEWSWIRE) -- Forward Pharma A/S (NASDAQ:FWP) (the “Company”) today announced that Dr. Claus Bo Svendsen , the Company’s Chief Executive Officer, will present at the 42 nd Annual Deutsche Bank Health Care Conference , being held May 3-4, 2017 in Boston, MA.
COPENHAGEN, Denmark , May 01, 2017 (GLOBE NEWSWIRE) -- Forward Pharma A/S (NASDAQ:FWP) (“we” or “Forward” or the “Company”) today provided an update on the Company’s strategic focus and related initiatives to reduce operating and personnel costs following the Settlement and License Agreement with
COPENHAGEN, Denmark , April 18, 2017 (GLOBE NEWSWIRE) -- Forward Pharma A/S (NASDAQ:FWP) (“we” or “Forward” or the “Company”), today reported financial results for the fourth quarter and year ended December 31, 2016 . Net income for the fourth quarter December 31, 2016 was $9.6 million while net
COPENHAGEN, Denmark , March 31, 2017 (GLOBE NEWSWIRE) -- Forward Pharma A/S (FWP) (“Forward Pharma” or the “Company”), a biopharmaceutical company that commenced development in 2005 of FP187, a proprietary formulation of DMF (dimethyl fumarate) for the treatment of inflammatory and neurological
COPENHAGEN, Denmark , March 01, 2017 (GLOBE NEWSWIRE) -- Forward Pharma A/S (NASDAQ:FWP) (“we” or the “Company”) today announced that its Board of Directors has appointed Claus Bo Svendsen , M.D., Ph.D. as Chief Executive Officer, effective March 1, 2017 .
COPENHAGEN, Denmark , Feb. 09, 2017 (GLOBE NEWSWIRE) -- Forward Pharma A/S (NASDAQ:FWP) (“we” or “Forward”) today announced that it has received a non-refundable cash fee of US$ 1.25 billion in connection with the execution and delivery of a Settlement and License Agreement with two wholly owned
Forward obtains shareholder approval for Settlement and License Agreement with Biogen COPENHAGEN, Denmark , Feb. 01, 2017 (GLOBE NEWSWIRE) -- Forward Pharma A/S (NASDAQ:FWP) (“we” or “Forward”) today announced that, at an extraordinary general meeting of its shareholders held on February 1, 2017
Biogen will pay Forward a non-refundable cash fee of $1.25 billion Forward may be eligible to receive royalties of 10% of net sales of Tecfidera beginning in 2021, and of 20% of net sales beginning in 2029, depending on the outcome of certain existing litigation and the receipt of regulatory
COPENHAGEN, Denmark , Nov. 29, 2016 (GLOBE NEWSWIRE) -- Forward Pharma A/S (NASDAQ:FWP) (“we” or “Forward” or the “Company”), today reported financial results for the third quarter ended September 30, 2016 . Net loss for the third quarter ended September 30, 2016 was $11.0 million , or $0.23 per
COPENHAGEN, Denmark , Nov. 02, 2016 (GLOBE NEWSWIRE) -- Forward Pharma A/S (FWP) (the “Company”), a biopharmaceutical company working to advance a proprietary formulation of DMF (dimethyl fumarate) for the treatment of inflammatory and neurological indications, today announced that Joel Sendek ,
COPENHAGEN, Denmark , Sept. 06, 2016 (GLOBE NEWSWIRE) -- Forward Pharma A/S (NASDAQ:FWP) (the “Company”), a biopharmaceutical company working to advance a proprietary formulation of DMF (dimethyl fumarate) for the treatment of inflammatory and neurological indications, today announced that Joel
COPENHAGEN, Denmark , Sept. 01, 2016 (GLOBE NEWSWIRE) -- Forward Pharma A/S (NASDAQ:FWP) (“we” or “Forward” or the “Company”), today reported financial results for the second quarter ended June 30, 2016 . Net loss for the second quarter ended June 30, 2016 was $15.1 million , or $0.32 per basic
COPENHAGEN, Denmark , June 06, 2016 (GLOBE NEWSWIRE) -- Forward Pharma A/S (Nasdaq:FWP) (the “Company”), a biopharmaceutical company working to advance a proprietary formulation of DMF (dimethyl fumarate) for the treatment of inflammatory and neurological indications, today announced that Joel
COPENHAGEN, Denmark , June 02, 2016 (GLOBE NEWSWIRE) -- Forward Pharma A/S (NASDAQ:FWP) (“We” or “Forward” or the “Company”), today reported financial results for the first quarter ended March 31, 2016 . Net loss for the first quarter ended March 31, 2016 was $16.9 million , or $(0.36) per basic
COPENHAGEN, Denmark , May 09, 2016 (GLOBE NEWSWIRE) -- Forward Pharma A/S (NASDAQ:FWP) (the “Company”) today announced that Dr. Karen Smith and Dr. Duncan Moore have been appointed to its Board of Directors as non-executive directors, expanding the Board to seven members. Dr.
COPENHAGEN, Denmark , May 02, 2016 (GLOBE NEWSWIRE) -- Forward Pharma A/S (NASDAQ:FWP) (the “Company”), a biopharmaceutical company working to advance a proprietary formulation of DMF (dimethyl fumarate) for the treatment of inflammatory and neurological indications, today announced that Joel
COPENHAGEN, Denmark , April 12, 2016 (GLOBE NEWSWIRE) -- Forward Pharma A/S (NASDAQ:FWP) (“We” or “Forward” or the “Company”), today reported financial results for the fourth quarter and year ended December 31, 2015 . Net loss for the fourth quarter and year ended December 31, 2015 was $9.6 million
COPENHAGEN, Denmark, Feb. 09, 2016 (GLOBE NEWSWIRE) -- Forward Pharma A/S ( FWP ) (the “Company”), a biopharmaceutical company working to advance a proprietary formulation of DMF (dimethyl fumarate) for the treatment of inflammatory and neurological indications, today announced that Joel Sendek,
COPENHAGEN, Denmark , Nov. 25, 2015 (GLOBE NEWSWIRE) -- Forward Pharma A/S (NASDAQ:FWP) ("We" or "Forward" or "Company"), today reported financial results for the third quarter ended September 30, 2015 . Net loss for the third quarter ended September 30, 2015 was $15.8 million , or $0.34 per share
COPENHAGEN, Denmark , Sept. 8, 2015 (GLOBE NEWSWIRE) -- Forward Pharma A/S (NASDAQ:FWP) ("We" or "Forward" or "Company"), today reported financial results for the second quarter ended June 30, 2015 . Net loss for the second quarter ended June 30, 2015 was $17.7 million , or $0.38 per share versus
COPENHAGEN, Denmark , Sept. 1, 2015 (GLOBE NEWSWIRE) -- Forward Pharma A/S (NASDAQ:FWP) (the "Company"), a biopharmaceutical company working to advance a proprietary formulation of DMF (dimethyl fumarate) for the treatment of inflammatory and neurological indications, today announced that Joel
COPENHAGEN, Denmark , June 19, 2015 (GLOBE NEWSWIRE) -- Forward Pharma A/S (Nasdaq:FWP) ("Forward" or the "Company"), a biopharmaceutical company working to advance a proprietary formulation of DMF (dimethyl fumarate) for the treatment of inflammatory and neurological indications, today announced
COPENHAGEN, Denmark , May 12, 2015 (GLOBE NEWSWIRE) -- Forward Pharma A/S (Nasdaq:FWP) ("Forward" or the "Company"), today reported financial results for the first quarter ended March 31, 2015 . Net income for the first quarter ended March 31, 2015 was $5.3 million , or $0.11 per share.
COPENHAGEN, Denmark , May 1, 2015 (GLOBE NEWSWIRE) -- Forward Pharma A/S (Nasdaq:FWP) (the "Company"), a biopharmaceutical company working to advance a proprietary formulation of DMF (dimethyl fumarate) for the treatment of inflammatory and neurological indications, today announced that Joel Sendek
Covers the Treatment of Multiple Sclerosis With 480 mg Daily Dose of DMF, the Active Ingredient in Tecfidera(R) COPENHAGEN, Denmark , April 27, 2015 (GLOBE NEWSWIRE) -- Forward Pharma A/S (Nasdaq:FWP) (the "Company") announced today that the Company received a decision to grant from the European
Forward Receives Senior Party Status Based on Earlier Filing Date COPENHAGEN, Denmark , April 14, 2015 (GLOBE NEWSWIRE) -- Forward Pharma A/S (Nasdaq:FWP) (the "Company") announced today that an interference was declared by the Patent Trial and Appeal Board (PTAB) on April 13, 2015 between the
COPENHAGEN, Denmark , April 9, 2015 (GLOBE NEWSWIRE) -- Forward Pharma A/S (Nasdaq:FWP) (the "Company" or "Forward") announced today an agreement among all of its pre-IPO shareholders to voluntarily lock-up their shares for an additional 365 days beyond the expiration of the original IPO lock-up.
COPENHAGEN, Denmark , March 25, 2015 (GLOBE NEWSWIRE) -- Forward Pharma A/S (Nasdaq:FWP), today reported financial results for the fourth quarter and year ended December 31, 2014 . Net loss for the fourth quarter and year ended December 31, 2014 was $2.0 million and $19.0 million , respectively.
COPENHAGEN, Denmark , March 16, 2015 (GLOBE NEWSWIRE) -- Forward Pharma A/S (Nasdaq:FWP), a biopharmaceutical company working to advance a proprietary formulation of dimethyl fumarate for the treatment of multiple sclerosis and other immune disorders such as psoriasis, today announced that Joel
COPENHAGEN, Denmark , Feb. 5, 2015 (GLOBE NEWSWIRE) -- Forward Pharma A/S (Nasdaq:FWP), a biopharmaceutical company working to advance a proprietary formulation of dimethyl fumarate for the treatment of multiple sclerosis and other immune disorders such as psoriasis, today announced that Joel
Covers Formulation of DMF, FP187, Into 2030 COPENHAGEN, Denmark , Nov. 24, 2014 (GLOBE NEWSWIRE) -- Forward Pharma A/S (Nasdaq:FWP) ("the Company") announced today that the Company received an issue notification from the United States Patent and Trademark Office (USPTO) regarding its patent
Alleges Infringement of Forward's German Utility Model COPENHAGEN, Denmark , Nov. 18, 2014 (GLOBE NEWSWIRE) -- Forward Pharma A/S (Nasdaq:FWP) announced today that it has filed a lawsuit against Biogen Idec GmbH , Biogen Idec International GmbH and Biogen Idec Ltd.
COPENHAGEN, Denmark , Nov. 14, 2014 (GLOBE NEWSWIRE) -- Forward Pharma A/S (the "Company") (Nasdaq:FWP), a biopharmaceutical company working to advance a proprietary formulation of dimethyl fumarate for the treatment of multiple sclerosis and other immune disorders such as psoriasis, announced
COPENHAGEN, Denmark , Nov. 14, 2014 (GLOBE NEWSWIRE) -- Forward Pharma A/S (Nasdaq:FWP), a biopharmaceutical company working to advance a proprietary formulation of dimethyl fumarate for the treatment of multiple sclerosis and other immune disorders such as psoriasis, today announced that Joel